Related by context. All words. (Click for frequent words.) 71 recurrent glioblastoma multiforme GBM 71 Glioblastoma multiforme GBM 71 recurrent glioblastoma multiforme 71 Glioblastoma multiforme 70 Glioblastomas 70 glioblastoma 69 HER2 positive metastatic breast 69 leukemia AML 69 Glioblastoma 68 recurrent glioblastoma 68 metastatic renal cell carcinoma 68 Gleevec resistant 68 epithelial tumors 68 malignant pleural mesothelioma 68 Glioblastoma Multiforme 68 hepatocellular carcinoma HCC 68 imatinib Gleevec ® 68 ara C 67 glioblastoma GBM 67 bevacizumab Avastin ® 67 pan HDAC inhibitor 67 basal cell carcinoma BCC 67 Chronic lymphocytic leukemia 67 erlotinib Tarceva ® 66 chronic lymphocytic leukemia CLL 66 refractory AML 66 Gliomas 66 Anaplastic 66 recurrent NSCLC 66 MGd 66 multiple myeloma MM 66 receptor tyrosine kinase inhibitor 66 AEG# 66 superficial bladder cancer 66 IMA# 66 CYT# potent vascular disrupting 66 malignant lymphomas 66 brain tumor glioblastoma multiforme 65 gastrointestinal stromal tumors 65 pancreatic adenocarcinoma 65 histone deacetylase HDAC inhibitor 65 astrocytomas 65 dasatinib Sprycel ® 65 Carfilzomib 65 Glioma 65 leukemia ALL 65 relapsed refractory multiple myeloma 65 acute myeloid leukemia AML 65 Glioblastoma Multiforme GBM 65 myelofibrosis polycythemia vera 65 TTF Therapy 65 nonsmall cell lung cancer 65 essential thrombocythemia ET 65 M2 subunit 65 gastrointestinal stromal tumors GIST 65 familial amyloidotic polyneuropathy FAP 65 cell lymphoma CTCL 65 leukemia CLL 65 Enzastaurin 65 metastatic colorectal 65 pegylated liposomal doxorubicin 65 Omacetaxine 65 non metastatic osteosarcoma 65 systemic fungal infections 65 grade cervical intraepithelial 64 essential thrombocythemia 64 gastrointestinal stromal tumor 64 Voreloxin 64 Acute lymphoblastic leukemia 64 metastatic melanoma 64 xenograft models 64 sorafenib tablets 64 sorafenib Nexavar ® 64 hematological cancers 64 immunotherapeutic agent 64 heavily pretreated 64 cutaneous T 64 proteasome inhibitor 64 invasive candidiasis 64 Philadelphia Chromosome Positive 64 acute leukemias 64 irinotecan chemotherapy 64 papillary renal cell carcinoma 64 Acute myeloid leukemia AML 64 metastatic bladder 64 Leukemias 64 metastatic renal cell 64 ependymoma 64 hematological malignancies 64 acute myelogenous leukemia AML 64 Acute myeloid leukemia 64 Chronic lymphocytic leukemia CLL 64 common hematologic malignancy 64 castrate resistant prostate cancer 64 pertuzumab 64 medulloblastoma 64 squamous cell carcinoma SCC 64 Basal cell 64 GISTs 64 antibody MAb 64 relapsed MM 64 ErbB2 positive 64 mycosis fungoides 64 Hepatocellular Carcinoma HCC 64 orally bioavailable 64 CA4P 64 anaplastic astrocytoma AA 64 HGS ETR1 64 INCB# [003] 64 Cutaneous T 64 unresectable stage 64 vinca alkaloid 63 differentiated thyroid 63 gastrointestinal stromal tumor GIST 63 serous ovarian cancer 63 cilengitide 63 Xanafide 63 TG# [003] 63 GW# [003] 63 docetaxel Taxotere R 63 trans retinoic acid 63 alkylating agent 63 Cotara ® 63 cutaneous T cell 63 follicular lymphoma FL 63 pancreatic NET 63 imatinib resistant 63 Crizotinib 63 nonmetastatic 63 BRAF inhibitor 63 Doxil ® 63 Proxinium TM 63 colorectal liver metastases 63 tumors GIST 63 MALT lymphoma 63 dasatinib Sprycel 63 indolent NHL 63 lymphoma subtypes 63 malignant gliomas 63 AA Amyloidosis 63 chronic myelogenous leukemia CML 63 YONDELIS 63 Vicinium TM 63 Myelodysplastic Syndrome MDS 63 trial evaluating PRX# 63 anaplastic 63 Acute Myeloid Leukaemia AML 63 acute promyelocytic leukemia APL 63 systemic RNAi therapeutic 63 HER2 positive cancers 63 lymphoma CTCL 63 hepatocellular cancer 63 recurrent glioma 63 demonstrated antitumor activity 63 anti angiogenic therapy 63 Mitoxantrone 63 recurrent GBM 63 oral prodrug 63 kidney urologic 63 Akt inhibitor 63 diagnosed glioblastoma multiforme 63 eosinophilic asthma 63 Acute Myelogenous Leukemia AML 63 Irinotecan 63 Imatinib mesylate 63 myeloid metaplasia 63 Hodgkin lymphoma NHL 63 chronic myeloid 63 bladder carcinoma 63 sarcomas 63 metastatic hormone refractory 63 virus HCV infection 63 bortezomib Velcade R 63 Blinatumomab 63 GRN# 63 Myelofibrosis 63 hypereosinophilic syndrome 63 Hsp# Inhibitor 63 Cloretazine 63 Fludara ® 63 targeted radiotherapeutic 62 relapsed multiple myeloma 62 thalidomide Thalomid 62 Surgical resection 62 monoclonal antibody conjugated 62 plus gemcitabine 62 advanced hepatocellular carcinoma 62 Chronic Lymphocytic Leukemia CLL 62 Relapsed Refractory 62 refractory chronic myeloid 62 hematologic malignancies 62 huN# DM1 62 imatinib Gleevec 62 signal transduction inhibitors 62 refractory chronic lymphocytic 62 fallopian tube carcinoma 62 colorectal carcinoma 62 chronic myeloid leukemia CML 62 neuroendocrine cancers 62 relapsed leukemia 62 PEGylated Fab fragment 62 relapsing remitting 62 investigational monoclonal antibody 62 mRCC 62 Malignant melanoma 62 sorafenib Nexavar 62 platinum refractory 62 docetaxel chemotherapy 62 Aplidin 62 lymphoid malignancies 62 Alocrest 62 HER2 + 62 trastuzumab Herceptin R 62 SCCHN 62 myeloproliferative diseases 62 lymphomas 62 radiation sensitizer 62 Bezielle 62 trastuzumab DM1 T DM1 62 Diabetic Macular Edema DME 62 Bavituximab 62 Epratuzumab 62 Pharmacokinetics PK 62 forodesine 62 osteosarcomas 62 KRAS wild 62 phase IIb clinical 62 advanced metastatic renal 62 Sym# 62 HGS ETR1 mapatumumab 62 cisplatin chemotherapy 62 standard chemotherapy regimens 62 FOLFOX6 62 Aflibercept 62 depsipeptide 62 orally administered inhibitor 62 refractory metastatic 62 nasopharyngeal cancer 62 situ CIS 62 ovarian carcinoma 62 Amrubicin 62 selective inhibitor 62 polycythemia vera PV 62 protein kinase inhibitor 62 Acute Myeloid Leukemia AML 62 photodynamic therapy PDT 62 CBLC# 62 sorafenib Nexavar R 62 gastric adenocarcinoma 62 CTAP# Capsules 62 sunitinib Sutent ® 62 taxane chemotherapy 62 Diffuse Large B 62 orthotopic model 62 candidemia 62 nasopharyngeal carcinoma 62 histologic subtype 62 Metastatic 62 gliomas 62 metastatic malignant melanoma 62 solid tumors 62 hematological malignancy 62 ELACYT 62 tyrosine kinase inhibitors TKIs 62 proliferator activated receptor 62 myeloproliferative disorders 62 cetuximab Erbitux ® 62 vinca alkaloids 62 Haptoglobin 62 neovascular diseases 62 docetaxel Taxotere 62 multi kinase inhibitor 62 astrocytoma 62 immunomodulator 62 chronic periodontitis 62 daunorubicin 62 pancreatic neuroendocrine 62 PNP inhibitor 62 castration resistant prostate cancer 62 carcinoid tumors 62 cell acute lymphoblastic 62 follicular non 62 ACTEMRA TM 62 gemcitabine Gemzar 62 HDACi 62 lenalidomide Revlimid R 62 Romidepsin 62 Pemetrexed 62 PKC# 62 myelodysplastic syndrome MDS 62 Carboplatin 62 Follicular lymphoma 62 carcinoid 62 Peginterferon alfa 2b 62 medullary thyroid cancer 62 oncolytic vaccine 62 PRTX 62 PCNSL 62 epithelioid 62 alvespimycin 62 gemcitabine carboplatin 62 IgG1 antibody 62 DermaVir 62 Pertuzumab 62 HER2 overexpression 62 hematological diseases 62 neratinib 62 thymoma 62 refractory acute myeloid 62 Sudhir Agrawal D.Phil 61 Copegus ribavirin 61 Phase #b/#a clinical 61 biliary tract cancer 61 bone metastasis 61 Chronic Myeloid Leukemia 61 acute coronary syndromes ACS 61 panobinostat 61 tumor xenograft models 61 Trastuzumab 61 Perifosine 61 pancreatic carcinoma 61 OncoVEX GM CSF 61 selective agonist 61 ZACTIMA 61 CLL SLL 61 mutated KRAS gene 61 Lymphocytic 61 non squamous NSCLC 61 Vidofludimus 61 Hodgkin lymphoma HL 61 refractory cutaneous T 61 alfa 2a 61 cutaneous melanoma 61 grade gliomas 61 Hepatocellular Carcinoma 61 metastatic malignant 61 Cell Lymphoma 61 hepatitis C HCV 61 metastatic colorectal carcinoma 61 delta isoform 61 metastatic colorectal cancer 61 B CLL 61 Nilotinib 61 5 fluorouracil leucovorin 61 p# biomarker 61 grade glioma 61 metastatic colon cancer 61 pegylated interferon alfa 2a 61 leiomyosarcoma 61 CEQ# 61 Bortezomib 61 relapsed refractory AML 61 virus HCV protease inhibitor 61 selective orally bioavailable 61 RNAi therapeutic targeting 61 antimetabolite 61 non resectable 61 alpha folate receptor 61 follicular NHL 61 recurrent ovarian cancer 61 mapatumumab 61 Cholangiocarcinoma 61 ALN TTR 61 fluoropyrimidine 61 invasive ductal 61 acute lymphoblastic 61 hepatocellular carcinoma 61 renal cell carcinoma 61 Fludarabine 61 TNF Tumor Necrosis Factor 61 Kit CD# positive 61 Sapacitabine 61 DOXIL 61 Malignant Melanoma 61 radezolid 61 Squalamine 61 glioblastoma multiforme 61 IRX 2 61 idiopathic myelofibrosis 61 unresectable tumors 61 tyrosine kinase inhibitor 61 Imprime PGG 61 lung carcinomas 61 oxidative stress inducer 61 seliciclib 61 EGFR HER2 61 recurrent metastatic 61 FluCAM arm 61 Maribavir 61 proteasome inhibitors 61 Relapsing remitting MS 61 targeting CD# 61 metastatic GIST 61 Alemtuzumab 61 Tyrima 61 chlorambucil 61 cleavable linker 61 huC# DM4 61 ADPKD 61 paclitaxel cisplatin 61 malignant lymphoma 61 ELOXATIN 61 myeloproliferative disorder 61 selective kinase inhibitor 61 Velcade bortezomib 61 Vidaza ® 61 refractory multiple myeloma 61 adecatumumab 61 cancer mCRC 61 evaluating tivozanib 61 ganetespib 61 Toxicities 61 NSCLC 61 KRAS mutations occur 61 azacytidine 61 Gliadel Wafer 61 anti angiogenic agent 61 Multiple myeloma 61 posterior uveitis 61 pediatric malignancies 61 anterior uveitis 61 polymerase inhibitor 61 Vandetanib 61 Papillary 61 EGFR tyrosine kinase inhibitor 61 colon carcinoma 61 FOLFOX chemotherapy 61 Genasense ® 61 FOLFIRI 61 PEG SN# 61 metastatic liver 61 Annamycin 61 metastatic renal 61 HCV protease 61 anticancer compound 61 Diabetic Macular Edema 61 metastatic pancreatic 61 ribavirin RBV 61 Talabostat 61 chronic granulomatous disease 61 JVRS 61 FLT3 61 metastatic gastric 61 Li Fraumeni Syndrome 61 acute myeloid 61 Tamibarotene 61 Dasatinib 61 leukemia CML 61 cetuximab Erbitux R 61 pediatric acute lymphoblastic 61 CHOP chemotherapy 61 Non Hodgkins lymphoma 61 refractory gout 61 atypical hemolytic uremic syndrome 61 prostate carcinoma 61 refractory anaplastic astrocytoma 60 histologies 60 Factor Receptor 60 gemcitabine cisplatin 60 TTR gene 60 Gastrointestinal Stromal Tumors 60 IMGN# 60 metaglidasen 60 AMN# [001] 60 refractory NSCLC 60 myeloid 60 renal carcinoma 60 pheochromocytoma 60 Deforolimus 60 leukaemias 60 Tarvacin 60 nucleoside analogue 60 cetuximab Erbitux 60 myelofibrosis MF 60 grade serous ovarian 60 oligodendrogliomas 60 MEK inhibitor 60 enzastaurin 60 PSMA ADC 60 neuroendocrine tumors 60 ribonucleotide reductase clinically validated 60 standard chemotherapy regimen 60 CIMZIA TM 60 gastric carcinoma 60 Panzem NCD 60 EGFR inhibitors 60 Azedra 60 Mantle Cell Lymphoma 60 Tarvacin TM 60 MT#/MEDI-# 60 Archexin 60 squamous cell cancer 60 IL# PE#QQR 60 anti leukemic 60 metastatic RCC 60 Ozarelix 60 nilotinib Tasigna ® 60 neoplasm 60 refractory CLL 60 Systemic lupus erythematosus SLE 60 squamous cell lung cancer 60 IMC A# 60 Temsirolimus 60 carcinoma HCC 60 HDAC Inhibitor 60 EGFR TKI 60 metastatic castration resistant 60 chimeric monoclonal antibody 60 CIMZIA TM certolizumab pegol 60 Viprovex TM 60 cisplatin gemcitabine 60 malignant brain 60 Malignant Glioma 60 Ph + ALL 60 Phase Ib II 60 intratumoral injection 60 HSP# inhibitor 60 BAY #-# 60 dasatinib 60 chemically modified siRNA 60 Monoclonal antibody 60 idarubicin 60 ovarian lung 60 bendamustine 60 metastatic kidney 60 skeletal metastases 60 ALN TTR# 60 Multiple Myeloma MM 60 histone deacetylase inhibitor 60 gefitinib Iressa 60 EndoTAGTM 1 60 sodium glucose cotransporter 60 HER2 receptor 60 alveolar rhabdomyosarcoma 60 nucleoside analogues 60 breast carcinomas 60 melphalan prednisone 60 relapsed ovarian cancer 60 AA amyloidosis 60 Seliciclib 60 K ras mutations 60 mda 7 60 Eculizumab 60 sunitinib malate 60 diagnosed GBM 60 Xeloda capecitabine 60 EpCAM 60 Intravenous CP 60 protein tyrosine phosphatase 1B 60 PI3K/mTOR 60 sarcomatoid 60 monoclonal anti 60 aflibercept VEGF Trap 60 Acute myelogenous leukemia 60 resistant ovarian cancer 60 Sezary syndrome 60 PEG interferon 60 oral antiviral 60 Squamous 60 virotherapy 60 IAP inhibitors 60 opioid induced constipation OIC 60 acute promyelocytic leukemia 60 CD# expressing 60 Erlotinib 60 glufosfamide 60 superficial basal cell carcinoma 60 pegylated interferon alpha 60 non squamous 60 hA# 60 Chronic Myeloid Leukemia CML 60 thetreatment 60 neoplasia CIN 60 oncolytic 60 mouse xenograft models 60 Metastatic Melanoma 60 lenalidomide dexamethasone 60 primary immunodeficiency PI 60 cisplatin resistant 60 unresectable locally advanced 60 vascular disrupting agent 60 mTOR inhibitor 60 RCW Breast Cancer 60 fosbretabulin 60 BRIM2 60 ANCA associated 60 selective antagonist 60 humanized monoclonal antibody 60 Gemzar ® 60 lymphoid tumors 60 INCB# [001] 60 Waldenstrom macroglobulinemia 60 mertansine 60 Adjuvant chemotherapy 60 metastatic neuroendocrine tumors 60 Rindopepimut 60 Mitomycin C 60 Naive Patients 60 systemic anaplastic large 60 Metastatic melanoma 60 ON #.Na 60 elacytarabine 60 ZK EPO 60 Gefitinib 60 prostate cancer PCa 60 PD LID 60 non metastatic resectable 60 Ceflatonin 60 MYCN amplification 60 BCR ABL inhibitors 60 Golimumab 60 Brentuximab Vedotin SGN 60 vWD 60 hyperoxaluria 60 myelodysplastic myeloproliferative diseases 60 systemic lupus erythematosus SLE 60 AKT inhibitor 60 lung metastases 60 B Cell Lymphoma 60 complement inhibitor eculizumab 60 chemotherapeutic regimen 60 selective inverse agonist 60 follicular lymphomas 60 DLBCL 60 ANG# 60 HER2 positive 60 neovascular 60 carcinomas 60 HQK 60 LHRH antagonists 60 TORISEL 60 5 fluorouracil 60 leukemias 60 Rituxan rituximab 60 HBeAg negative 60 acetonide FA 60 Ribavirin causes 60 lymphoblastic leukemia 60 novel VDA molecule 60 demethylating agent 60 evaluating Xcytrin 60 compound AEZS 60 Acute Myeloid Leukemia 60 inhibitor RG# 60 systemic ALCL 60 dacarbazine DTIC 60 humanized monoclonal antibodies 60 cytotoxin 60 docetaxel Taxotere ® 60 IV NSCLC 60 Fludara 60 JAK1 60 seminoma 60 paclitaxel Taxol R 60 INGN 60 Bosutinib 60 pomalidomide 60 chemotherapeutic agent 60 Antitumor Activity 60 TRAIL R2 60 hematologic cancers 60 Follicular Lymphoma 60 MELAS 60 T#I [002] 59 imatinib mesylate 59 acute GvHD 59 assessing T DM1 59 stage IIIB IV 59 MEK inhibitors 59 HuMax EGFr 59 carboplatin paclitaxel 59 EGFr 59 unresectable 59 epithelial cancers 59 MCyR 59 vascular disrupting agents 59 ENMD # 59 Quinamed 59 MPS IVA 59 paclitaxel Taxol ® 59 Albuferon TM 59 adalimumab Humira 59 mCRC 59 luteinizing hormone releasing 59 Tesetaxel 59 Nexavar ® 59 immune modulating 59 transplantation HCT 59 Ph + acute lymphoblastic 59 brostallicin 59 5 FU leucovorin 59 HuLuc# 59 DermaVir Patch 59 plus DOXIL 59 Inhaled nitric oxide 59 RhuDex R 59 isoform selective 59 temozolomide TMZ 59 Chronic Lymphocytic Leukemia 59 modified glutathione analog 59 LHRH receptor positive 59 Alfacell proprietary ribonuclease 59 Pegasys ® 59 Zybrestat 59 ocular formulation 59 frontotemporal dementia FTD 59 neuroblastomas 59 adriamycin 59 obatoclax 59 mitomycin 59 estramustine 59 alkylating agents 59 Metastatic Colorectal Cancer 59 Darinaparsin 59 Valortim R 59 Ibritumomab Tiuxetan 59 nonmelanoma skin cancers 59 gemcitabine chemotherapy 59 bladder ovarian 59 renal cell carcinomas 59 irinotecan doxorubicin oxaliplatin paclitaxel 59 Phase Ib clinical 59 Folfox 59 OMP #R# 59 Janus kinase 59 AAG geldanamycin analog 59 CANCIDAS 59 flavopiridol 59 CMV infection 59 Bevacizumab 59 gastrointestinal stromal tumors GISTs 59 VEGFR2 inhibitor 59 Acute Leukemia 59 refractory indolent non 59 bosutinib 59 PARP inhibitor 59 microwave hyperthermia 59 stage IIIb IV 59 relapsing remitting MS RRMS 59 dacarbazine 59 antiangiogenic agent 59 BARACLUDE ® 59 RhuDex ® 59 hematologic disorders 59 MabCampath 59 Advanced Renal Cell 59 monoclonal antibodies MAbs 59 kinase inhibition 59 myeloproliferative 59 Extensively drug 59 liposomal formulation 59 Helicobacter pylori H. pylori 59 interstitial cystitis IC 59 stage IIIB 59 gastric cancers 59 nucleoside analog 59 prophylactic vaccine 59 relapsing multiple sclerosis 59 squamous 59 Allovectin 7 59 refractory colorectal cancer 59 acyclovir Lauriad R 59 nucleotide analog 59 teriflunomide 59 idiopathic pulmonary fibrosis IPF 59 oropharyngeal candidiasis 59 Apaziquone 59 trans retinoic acid ATRA 59 hepatoma 59 VELCADE melphalan 59 effector function 59 NXL# 59 HGS ETR2 59 lomitapide 59 commercialize deforolimus 59 thymalfasin 59 PhG alpha 1 59 SSc 59 Daclizumab 59 non thiazolidinedione TZD 59 completely resected 59 malignant fibrous histiocytoma 59 Elotuzumab 59 hepatorenal syndrome 59 leukemia APL 59 mitogen activated ERK kinase 59 FluCAM 59 Hedgehog Pathway Inhibitor 59 relapsing remitting multiple sclerosis 59 locoregional disease 59 haematological malignancies 59 mCRC patients 59 Epstein Barr Virus EBV 59 Osteosarcoma 59 c MET 59 Tyrosine Kinase Inhibitors 59 CYT# 59 chemotherapy cisplatin 59 lung pancreatic 59 Medullary thyroid cancer 59 triphendiol 59 anti EGFR antibody 59 CCX# 59 delafloxacin 59 toenail onychomycosis 59 PI3K inhibitors 59 meropenem 59 Bayer HealthCare Onyx Pharmaceuticals 59 Pleural mesothelioma 59 Burkitt lymphoma 59 CDDO Im 59 cervical carcinoma 59 registrational trial 59 hepatitis C viral infection 59 SCH # 59 humanised monoclonal antibody 59 solithromycin 59 myeloproliferative neoplasms 59 myelofibrosis 59 metastatic carcinoma 59 novel histone deacetylase 59 bleomycin 59 synovial sarcoma 59 Medulloblastoma 59 metastatic CRC 59 relapsed CLL 59 anthracyclines taxanes 59 paclitaxel carboplatin 59 bortezomib Velcade 59 imatinib resistance 59 GIST 59 cytotoxic chemotherapy 59 TREANDA 59 IAP inhibitor 59 ATTR 59 TTR amyloidosis 59 tigecycline 59 immunomodulatory therapy 59 antiangiogenic therapy 59 BR.# 59 radiation chemoradiation 59 immunotoxin 59 erythematosus 59 radiochemotherapy 59 pulmonary metastasis 59 Friedreich Ataxia FRDA 59 Pralatrexate 59 homozygous familial hypercholesterolemia 59 PARP inhibitors 59 GPNMB 59 hepatocellular carcinomas 59 cytogenetic abnormalities 59 doublet chemotherapy 59 IV metastatic melanoma 59 relapsed Acute Myeloid 59 Response Evaluation Criteria 59 brain metastases 59 MAGE A3 ASCI 59 SPRYCEL ® 59 neuroblastoma tumors 59 Virulizin ® 59 nilotinib 59 transplantation HSCT 59 relapsing remitting MS 59 humanised antibody 59 Obatoclax 59 refractory CTCL 59 Tyrosine Kinase Inhibitor 59 simplex virus 59 gastrin analogue TT 59 OHR/AVR# 59 phase IIb trial 59 AAV2 59 pituitary adenomas 59 TELINTRA 59 Laquinimod 59 relapsed acute lymphoblastic 59 OMP #M# 59 pegylated alpha interferon 59 GBMs 59 previously untreated follicular 59 sJIA 59 alkylating 59 systemic lupus erythematosus 59 poly ADP ribose polymerase 59 proteasome inhibitor bortezomib 59 chemotherapeutic drug 59 hormone refractory metastatic prostate 59 denileukin diftitox 59 Ceplene/IL-2 59 galiximab 59 HER2 antibody 59 Anthracyclines 59 chronic eosinophilic leukemia 59 myeloid leukemia 59 Immunotherapeutic 59 phase IIb study 59 therapeutic monoclonal antibody 59 antiproliferative effects 59 cryptococcosis 59 mutated KRAS 59 embryonal rhabdomyosarcoma 59 geographic atrophy 59 relapsed acute myelogenous 59 chemoradiotherapy 59 recurrent genital herpes 59 cediranib 59 lumiliximab 59 VEGF receptor 59 immunostimulatory 59 viral kinetics 59 Lymphomas 59 prostate cancer HRPC 59 pleomorphic 59 combretastatin A4 phosphate CA4P 59 cutaneous squamous cell carcinoma 59 dose escalation Phase 59 interferon alfa 59 NMIBC 59 Duchenne muscular dystrophy DMD 59 lung adenocarcinomas 59 Arsenic trioxide 59 5 HT4 receptor 59 Malignant glioma 59 chemotherapeutic regimens 59 ThermoDox R 58 targeted antifolate 58 Unresectable 58 Aliskiren 58 demyelinating disease 58 polymerase inhibitors 58 VZV 58 ifosfamide 58 resectable 58 trabectedin 58 follicular lymphoma 58 locoregional recurrence 58 lymphocytic leukemia 58 Angioedema 58 BMS# 58 advanced unresectable 58 nucleoside 58 Gleevec imatinib 58 subependymal giant cell 58 ceftazidime 58 cell malignancies 58 rALLy clinical trial 58 Tumor Necrosis Factor 58 paraganglioma 58 angiogenesis inhibitor 58 HCD# [002] 58 sunitinib Sutent 58 Castration Resistant Prostate Cancer 58 ACZ# 58 INxin 58 prostate adenocarcinoma 58 precursor lesions 58 MT# MEDI 58 JAK inhibitor 58 anticancer therapies 58 squamous cell 58 TACE 58 riociguat 58 Combination REOLYSIN R 58 hematologic toxicity 58 epithelial ovarian 58 Atiprimod 58 Rilonacept 58 monocytic 58 tiuxetan 58 Crohn disease CD 58 delta gamma agonist 58 small molecule tyrosine 58 chemotherapy induced neutropenia 58 acne vulgaris 58 beta lactamase inhibitor 58 cytogenetic responses 58 paclitaxel Taxol 58 FOLFIRI alone 58 pilocytic astrocytomas 58 Dapagliflozin 58 invasive aspergillosis 58 CIMZIA ™ 58 cytoreduction 58 5 Fluorouracil 58 hepatitis C genotype 58 TLK# 58 Chemophase 58 cervical intraepithelial neoplasia 58 paragangliomas 58 anaplastic astrocytoma 58 Phase #/#a trial 58 FOLFOX6 chemotherapy regimen 58 Ofatumumab 58 advanced carcinoid 58 mTOR mammalian target 58 CINTREDEKIN BESUDOTOX 58 medulloblastomas 58 chemoradiation